Home › Kanser ng Endometrium › Texas › San Antonio
Pag-aaral pangklinika para sa Kanser ng Endometrium sa San Antonio, TX
Isang pag-aaral para sa Kanser ng Endometrium ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa San Antonio. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
A Study of PHST001 in Advanced Solid Tumors
Nagre-recruitPhase 1
- START Center for Cancer Research - San Antonio, San Antonio
- University of Texas (UT) Health, San Antonio
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Nagre-recruitPhase 1/2
- New Experimental Therapeutics of San Antonio - NEXT Oncology, San Antonio
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Nagre-recruitPhase 1/2
- NEXT Oncology San Antonio, San Antonio
- START Texas, San Antonio
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
Nagre-recruitPhase 3
- Texas Oncology-San Antonio Medical Center ( Site 8001), San Antonio
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Nagre-recruitPhase 1/2
- START Center for Cancer Research, San Antonio
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Nagre-recruitObservasyonal na pag-aaral
- The University of Texas Health Science Center at San Antonio, San Antonio
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Nagre-recruitPhase 1
- START - San Antonio, San Antonio
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
Nagre-recruitPhase 3
- USOR - TX Oncology - SA NE, San Antonio
- NEXT San Antonio, San Antonio
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
Nagre-recruitPhase 3
- Research Site, San Antonio
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
Nagre-recruitPhase 1
- NEXT San Antonio, San Antonio
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
Nagre-recruitPhase 1
- UT Health San Antonio - MD Anderson Cancer Center, San Antonio
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Nagre-recruitPhase 1
- Normunity Investigational Site, San Antonio
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Nagre-recruitPhase 1/2
- South Texas Accelerated Research Therapeutics, LLC, San Antonio
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Nagre-recruitPhase 1/2
- UT Health Mays Cancer Center, San Antonio
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
Nagre-recruitPhase 1
- START - San Antonio, San Antonio
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Nagre-recruitPhase 1/2
- Texas Oncology - San Antonio, San Antonio
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
Nagre-recruitPhase 3
- Texas Oncology San Antonio Medical Center, San Antonio
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Nagre-recruitPhase 1
- NEXT Virginia, LLC, San Antonio
- South Texas Accelerated Research Therapeutics, LLC, San Antonio
Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
Nagre-recruitPhase 1
- NEXT San Antonio, San Antonio
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Nagre-recruitPhase 1/2
- START San Antonio, San Antonio
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Nagre-recruitPhase 1
- NEXT Oncology, San Antonio
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Nagre-recruitPhase 1/2
- START, San Antonio
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
Nagre-recruitPhase 1
- NEXT Texas LLC - San Antonio, San Antonio
- START San Antonio, LLC, San Antonio
A Study of Lorigerlimab in Participants With Advanced Solid Tumors
Nagre-recruitPhase 2
- START San Antonio, San Antonio
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Nagre-recruitPhase 1/2
- NEXT Oncology, San Antonio
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Nagre-recruitPhase 1
- Dren Investigational Site, San Antonio
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
Nagre-recruitPhase 2/3
- Texas Oncology-San Antonio Medical Center, San Antonio
Pag-aaral para sa Kanser ng Endometrium sa ibang lungsod
- Houston, TX68 pag-aaral
- New York City, NY52 pag-aaral
- Boston, MA50 pag-aaral
- Arlington, VA39 pag-aaral
- Nashville, TN38 pag-aaral
- Los Angeles, CA34 pag-aaral
- St. Louis, MO29 pag-aaral
- Philadelphia, PA28 pag-aaral
- Columbus, OH25 pag-aaral
- Oklahoma City, OK25 pag-aaral
- Chicago, IL25 pag-aaral
- Queens, NY25 pag-aaral
Iba pang pag-aaral sa San Antonio
- Non-Small Cell Lung Cancer59 pag-aaral
- Kanser sa Suso47 pag-aaral
- Colorectal Cancer46 pag-aaral
- Metastatic Cancer44 pag-aaral
- Kanser (lahat ng uri)41 pag-aaral
- Obesity40 pag-aaral
- Type 2 Diabetes37 pag-aaral
- Overweight34 pag-aaral
- Kanser sa Ovary31 pag-aaral
- Kanser sa Pancreas31 pag-aaral
- Kanser sa Prostate28 pag-aaral
- Kanser sa Baga26 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.